Article Figures & Data
Tables
Characteristics n = 256 (%) Age (years) ≤ 60 years 137 (53.52) > 60 years 119 (46.48) Gender Male 157 (61.33) Female 99 (38.67) Pathology Adenocarcinoma 201 (78.52) Squamous cell carcinoma or adenosquamous
carcinoma44 (17.19) Other subtypes 11 (4.3) Driver gene EGFR Wild type (-) 172 (67.19) Mutant type (+) 84 (32.81) Driver gene ALK Wild type (-) 248 (98.02) Mutant type (+) 5 (1.98) Unclear 3 Clinical staging Stage III B 12 (4.69) Stage IV 244 (95.31) Metastasis Number of metastases ≤ 3 155 (60.55) Number of metastases > 3 101 (39.45) History of tumor surgery Yes 136 (53.13) No 120 (46.88) Number of previous chemotherapy regimens 2 146 (57.03) > 2 110 (42.97) Previous chemotherapeutic regimen Pemetrexed + Platinum 182 (71.09) Docetaxel + Platinum 165 (64.45) Paclitaxel + Platinum 81 (31.64) Vinorelbine + Platinum 67 (26.17) Gemcitabine + Platinum 138 (53.91%) History of radiotherapy No 154 (60.16) Yes 102 (39.84) History of targeted medication No 115 (44.92) Yes 141 (55.08) ECOG 0 54 (21.09) 1 202 (78.91) - 2
Results of the prognostic factor analysis of patients from the anlotinib group (univariate analysis)
Item PFS OS P HR (95%CI) P HR (95%CI) Age 0.003 0.639 (0.478, 0.856) 0.456 1.126 (0.824, 1.538) Post-treatment ECOG 0.445 1.164 (0.789, 1.717) < 0.001 2.219 (1.489, 3.836) Post-treatment granulocytes/lymphocytes < 0.001 2.013 (1.405, 2.548) < 0.001 2.651 (1.884, 3.732) Pre-randomization maximal target lesion length 0.360 1.144 (0.857, 1.528) < 0.001 2.049 (1.498, 2.803) Hypertension < 0.001 0.466 (0.341, 0.637) 0.004 0.617 (0.445, 0.854) Hand-foot syndrome < 0.001 0.476 (0.354, 0.640) < 0.001 0.483 (0.348, 0.669) Oral mucositis 0.031 0.693 (0.497, 0.967) 0.051 0.691 (0.476, 1.001) Prolonged QT interval in ECG 0.010 0.646 (0.463, 0.900) 0.741 0.942 (0.662, 1.341) Hyperglycemia 0.007 0.662 (0.491, 0.892) 0.735 1.059 (0.759, 1.477) Hypertriglyceridemia < 0.001 0.453 (0.329, 0.623) < 0.001 0.462 (0.335, 0.639) Hypercholesterolemia 0.001 0.558 (0.392, 0.794) 0.004 0.629 (0.540, 1.173) Hyper-low density lipoproteinemia 0.001 0.502 (0.330, 0.762) 0.321 0.830 (0.516, 1.320) Elevated thyroid stimulating hormone 0.001 0.591 (0.434, 0.805) 0.004 0.620 (0.449, 0.857) Elevated alkaline phosphatase 0.008 1.519 (1.118, 2.065) 0.005 1.609 (1.159, 2.234) Hypocalcemia 0.314 1.303 (0.778, 2.184) 0.012 1.876 (1.146, 3.071) Hyponatremia 0.092 1.337 (0.954, 1.875) 0.001 1.971 (1.390, 2.795) Hypomagnesemia 0.026 0.485 (0.256, 0.918) 0.468 0.789 (0.416, 1.497) - 3
Results of the prognostic factor analysis of patients in the anlotinib group (multivariate analysis)
Item PFS OS P HR (95%CI) P HR (95%CI) Post-treatment ECOG score 0.002 2.073 (1.315, 3.269) Post-treatment granulocytes/lymphocytes ratio < 0.001 2.183 (1.523, 3.130) < 0.001 2.423 (1.642, 3.576) Pre-randomization maximal target lesion length 0.003 1.690 (1.190, 2.400) Hypertension 0.040 0.688 (0.481, 0.983) Hand-foot syndrome 0.002 0.582 (0.415, 0.815) Hyperglycemia 0.007 0.632 (0.453, 0.884) Hypertriglyceridemia 0.002 0.545 (0.569, 1.535) 0.002 0.520 (0.347, 0.778) Elevated thyroid stimulating hormone 0.003 0.573 (0.399, 0.822) Elevated alkaline phosphatase 0.044 1.425 (1.010, 2.011) - 4
PFS and OS of each variable from the subgroups were divided on the basis of the cutoff values
PFS OS Median P Median P Post-treatment ECOG 0.0031 0-1 point 9.93 2-3 point 7.26 Post-treatment granulocytes/lymphocytes ratio 0.0008 < 0.0001 ≤ 3.1 5.97 11.16 > 3.1 4.45 8.18 Pre-randomization maximal target lesion length (mm) 0.0002 ≤ 72 10.38 > 72 7.98 Hypertension < 0.0001 Yes 5.65 No 3.42 Hand-foot syndrome < 0.0001 Yes 6.51 No 3.80 Hyperglycemia 0.0003 Yes 5.60 No 3.93 Hypertriglyceridemia < 0.0001 < 0.0001 Yes 5.67 10.23 No 3.41 7.29 Elevated thyroid stimulating hormone < 0.0001 Yes 5.66 No 3.61 Elevated alkaline phosphatase 0.0286 Yes 4.23 No 5.32